- Asymchem acquires Pfizer’s UK API plant and development labs.
- Operations scheduled to start in June, hiring 100 workers by year-end.
Asymchem is expanding its global footprint by taking over Pfizer’s former small molecule active pharmaceutical ingredient (API) pilot plant and development laboratories in Sandwich, England.
Last November, Pfizer’s $3.5 billion cost-cutting campaign resulted in laying off 500 of the 940 employees at the Sandwich site. While small molecule production was cut, some functions were retained at a reduced scale. The site holds historical significance as the birthplace of Viagra.
Asymchem plans to commence operations at the development labs in June and at the API plant in August. The company aims to hire 100 workers by the end of this year, including many former Pfizer employees. “We are excited to integrate experienced talent from Pfizer into our team,” the company stated.
Looking forward, Asymchem intends to enhance the site’s capabilities to include peptides, oligonucleotides, and additional sustainability features.
The company says it is “excited” to join the European pharmaceutical manufacturing community, CEO Hao Hong, Ph.D, said in the release. “Meeting the needs of our clients in bringing manufacturing into the Western market will continue to be part of our long-term strategy to meet overall global business demands,” Hong added.
Meet Asymchem at CDMO Live in June 13th
Overview of outsourcing trends 
